Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the month of April 2026. The report details a significant corporate action regarding the company's listing structure on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notice of a listing change rather than a financial results report.
Material Changes
- Listing Transition: On April 20, 2026, the company commenced trading of its ordinary shares on Nasdaq, replacing the previous listing of American Depositary Shares (ADSs).
- Exchange Completion: A mandatory exchange of all outstanding ADSs for ordinary shares was completed as of April 20, 2026, at a ratio of one ADS for one ordinary share.
- Trading Details: The last trading day for ADSs was April 17, 2026. Ordinary shares trade under the same ticker symbol "ASND" with CUSIP number K08588103 and ISIN DK0060606333.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future performance, specific risks, contingencies, or unusual items. The document focuses solely on the administrative completion of the ADS-to-ordinary share exchange.
Investor Verification Checklist
- Confirm that the ticker symbol "ASND" now represents ordinary shares rather than ADSs.
- Verify the new CUSIP (K08588103) and ISIN (DK0060606333) for trading purposes.
- Ensure brokerage accounts reflect the conversion of any previously held ADSs into ordinary shares.